About VIAN Therapeutics

VIAN Therapeutics develops a potent, orally active peptide drug that selectively inhibits angiogenesis and vascular permeability, addressing the underlying causes of retinal diseases such as age-related macular degeneration and diabetic macular edema. Their lead product, VIAN-c4551, offers a convenient daily eye drop alternative to invasive intravitreal injections, improving patient adherence and therapeutic outcomes.

```xml <problem> Current treatments for retinal diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME) often involve invasive intravitreal injections, leading to poor patient adherence and suboptimal vision recovery in a significant percentage of patients. These injections target vascular endothelial growth factor (VEGF), but VEGF inhibition alone is not always sufficient to halt disease progression. The invasiveness, inconvenience, and financial burden of existing anti-VEGF therapies present significant challenges for patients. </problem> <solution> VIAN Therapeutics is developing VIAN-c4551, a topically administered, orally active peptide drug designed to selectively inhibit angiogenesis and vascular permeability in retinal diseases. VIAN-c4551 offers a convenient, once-daily eye drop alternative to intravitreal injections, potentially improving patient compliance and therapeutic outcomes. The drug acts on angiogenic endothelial cells to potently inhibit their response to proangiogenic factors, including VEGF and Ang-2, providing a more complete antiangiogenic profile. By addressing multiple angiogenic factors, VIAN-c4551 aims to overcome the limitations of current anti-VEGF therapies and offer improved efficacy and safety. </solution> <features> - Topically active formulation for convenient, once-daily administration as an eye drop - Selective inhibition of angiogenesis and vascular permeability - Potent inhibition of angiogenic endothelial cell response to VEGF and Ang-2 - Demonstrated ocular penetration and longevity, maintaining therapeutic levels in the retina - Designed to improve patient adherence compared to invasive intravitreal injections - Aims to provide a more complete antiangiogenic profile compared to single-target VEGF inhibitors </features> <target_audience> The primary target audience includes patients with retinal diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME), as well as ophthalmologists and retina specialists seeking more convenient and effective treatment options. </target_audience> ```

What does VIAN Therapeutics do?

When was VIAN Therapeutics founded?

VIAN Therapeutics was founded in 2023.

Founded

2023

Employees

5 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

energy flexibility software underground pipe robots AI voice (2021+)

Start Searching

VIAN Therapeutics

AI-Generated Overview – may contain errors

Executive Summary

viantx.com 100+

Founded 2023

Funding

No funding information available.

Team (5+)

No team information available.

Company Description

Problem

Current treatments for retinal diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME) often involve invasive intravitreal injections, leading to poor patient adherence and suboptimal vision recovery in a significant percentage of patients. These injections target vascular endothelial growth factor (VEGF), but VEGF inhibition alone is not always sufficient to halt disease progression. The invasiveness, inconvenience, and financial burden of existing anti-VEGF therapies present significant challenges for patients.

Solution

VIAN Therapeutics is developing VIAN-c4551, a topically administered, orally active peptide drug designed to selectively inhibit angiogenesis and vascular permeability in retinal diseases. VIAN-c4551 offers a convenient, once-daily eye drop alternative to intravitreal injections, potentially improving patient compliance and therapeutic outcomes. The drug acts on angiogenic endothelial cells to potently inhibit their response to proangiogenic factors, including VEGF and Ang-2, providing a more complete antiangiogenic profile. By addressing multiple angiogenic factors, VIAN-c4551 aims to overcome the limitations of current anti-VEGF therapies and offer improved efficacy and safety.

Features

Topically active formulation for convenient, once-daily administration as an eye drop

Selective inhibition of angiogenesis and vascular permeability

Potent inhibition of angiogenic endothelial cell response to VEGF and Ang-2

Demonstrated ocular penetration and longevity, maintaining therapeutic levels in the retina

Designed to improve patient adherence compared to invasive intravitreal injections

Aims to provide a more complete antiangiogenic profile compared to single-target VEGF inhibitors

Target Audience

The primary target audience includes patients with retinal diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME), as well as ophthalmologists and retina specialists seeking more convenient and effective treatment options.